Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence F Eichenfield

Showing results (241-250 of 376) with videos related to

Pageof 38
Sort By:
Dermatology and Therapy|May 17, 2026
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 TrialMelinda Gooderham, Christopher G Bunick, JiaDe Yu, et al.
The Journal of Dermatological Treatment|June 28, 2021
Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapyPeter A Lio, Eric L Simpson, George Han, et al.
American Journal of Clinical Dermatology|October 20, 2022
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III StudiesLisa Bloudek, Lawrence F Eichenfield, Jonathan I Silverberg, et al.
Advances in Therapy|November 1, 2022
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with DupilumabAndrew Blauvelt, Andreas Wollenberg, Lawrence F Eichenfield, et al.
Paediatric Drugs|May 24, 2023
Diagnosis and Management of Pediatric Chronic Hand Eczema: The PeDRA CACHES SurveyMichael A Haft, Helen H Park, Stephanie S Lee, et al.
Journal of the American Academy of Dermatology|July 30, 2023
A multimodal initiative improves general pediatric provider management of atopic dermatitis in children: A prospective interventional studyStephanie S Lee, Anshika Kaushik, Nicola Natsis, et al.
Journal of Drugs in Dermatology : JDD|February 4, 2021
Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With ImpetigoLawrence A Schachner, Anneke Andriessen, Latanya T Benjamin, et al.
Journal of Drugs in Dermatology : JDD|December 2, 2025
Clindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: A Pooled Analysis by AgeLeon H Kircik, Julie C Harper, Hilary Baldwin, et al.
The Journal of Dermatological Treatment|November 10, 2024
Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 yearsAndreas Wollenberg, Masanori Ikeda, Chia-Yu Chu, et al.
The Journal of Pediatrics|August 5, 2006
Congenital localized sclerodermaFrancesco Zulian, Cristina Vallongo, Sheila Knupp Feitosa de Oliveira, et al.
Pageof 38

Showing results (241-250 of 376) with videos related to

Sort By:
Pageof 38
Dermatology and Therapy|May 17, 2026
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 TrialMelinda Gooderham, Christopher G Bunick, JiaDe Yu, et al.
The Journal of Dermatological Treatment|June 28, 2021
Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapyPeter A Lio, Eric L Simpson, George Han, et al.
American Journal of Clinical Dermatology|October 20, 2022
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III StudiesLisa Bloudek, Lawrence F Eichenfield, Jonathan I Silverberg, et al.
Advances in Therapy|November 1, 2022
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with DupilumabAndrew Blauvelt, Andreas Wollenberg, Lawrence F Eichenfield, et al.
Paediatric Drugs|May 24, 2023
Diagnosis and Management of Pediatric Chronic Hand Eczema: The PeDRA CACHES SurveyMichael A Haft, Helen H Park, Stephanie S Lee, et al.
Journal of the American Academy of Dermatology|July 30, 2023
A multimodal initiative improves general pediatric provider management of atopic dermatitis in children: A prospective interventional studyStephanie S Lee, Anshika Kaushik, Nicola Natsis, et al.
Journal of Drugs in Dermatology : JDD|February 4, 2021
Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With ImpetigoLawrence A Schachner, Anneke Andriessen, Latanya T Benjamin, et al.
Journal of Drugs in Dermatology : JDD|December 2, 2025
Clindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: A Pooled Analysis by AgeLeon H Kircik, Julie C Harper, Hilary Baldwin, et al.
The Journal of Dermatological Treatment|November 10, 2024
Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 yearsAndreas Wollenberg, Masanori Ikeda, Chia-Yu Chu, et al.
The Journal of Pediatrics|August 5, 2006
Congenital localized sclerodermaFrancesco Zulian, Cristina Vallongo, Sheila Knupp Feitosa de Oliveira, et al.
Pageof 38